Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Piroctone Olamine at 1% is recommended for reducing scalp inflammation and encouraging hair growth. The user seeks recommendations for UK shampoos/conditioners containing this ingredient.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation is about evaluating the ingredients in Davines VOLU shampoo for potential red flags. The user is concerned about which ingredients to avoid despite the shampoo being sulfate-free.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.

A 25-year-old is using vinpocetine to enhance the absorption of topical Minoxidil for hair loss. They also use a hair tonic and supplement with Glycine, Taurine, Creatine, and Citrulline.

A 2-week journey with Pyri, which is producing positive effects on hair texture and reduced shedding; Minoxidil and derma needling are being used as treatments.

The conversation is about whether vellus hair should be included in hair fall counts, with data showing daily hair loss. The consensus is that shedding, including vellus hair, is normal and within physiological limits.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

Eucapill 2% used for 1 month reduced shedding from 200 to 10/20 hairs daily with no side effects. Finasteride caused side effects like ED and watery semen.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.